Study of two drugs for recurrent ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of two targeted drugs (mirvetuximab soravtansine and suvemcitug) for people with ovarian cancer that has come back after platinum-based chemotherapy and is no longer responding to it. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have a specific type of ovarian cancer (high-grade serous) that has returned within 6 months of finishing platinum chemotherapy.
- Your tumor must have a certain marker called folate receptor alpha (FRa), which will be checked through a test.
- You have had 1 to 3 previous treatments for your cancer, including a drug called bevacizumab (Avastin).
- You are generally in good health (able to do daily activities) and have at least one tumor that can be measured by scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
This study tests a drug called mirvetuximab soravtansine (MIRV) for people with ovarian cancer that has a specific protein (FRα). It aims to see how well the drug works in real-world settings, either alone or with other treatments.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This study tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian cancer that has a specific protein (FRα). It's real-world research to see how well the drug works and how it affects people's daily lives.
This trial tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) for women whose ovarian cancer stopped responding to platinum chemotherapy. The goal is to see if the combination helps shrink or slow the cancer.
Hear when a new PROC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.